Enovis Corporation
NYSE:ENOVMedical - Devices
+$0.73 today
- Market cap
- $1.56B
- Beta
- 1.49
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$20.02
Volume 0.88M
Average 0.99M
ENOV EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Enovis CorporationNYSE: ENOV
EBITDA · Q1 FY2026 · quarter ended Apr 2026
EBITDA growth accelerates
Q1 FY2026 EBITDA of $93.16M rose 300.3% year over year, ahead of the -58.6% change in trailing-twelve-month EBITDA.
Context
- EBITDA amounted to 36.9% of revenue in FY2025, up 14.1 pp from a year earlier.
- EBITDA increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of $608.82M (+173.3%) for the fiscal year ending Dec 2026, a step up from the -72.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterApr 2026
- $93.16M+121.9% QoQ
- Last fiscal yearDec 2025
- -$830.22M-72.6% YoY
- LTMApr 2026
- -$748.33M-58.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +300.3% | +171.6% | -128.6 pp |
| 1 year | -72.6% | +173.3% | +245.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (830.22M) USD
- Year-over-year change
- -72.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (830.22M) | -72.6% |
| FY2024 | 2024-12-31 | (481.03M) | -383.4% |
| FY2023 | 2023-12-31 | 169.73M | -29.8% |
| FY2022 | 2022-12-31 | 241.69M | +42.0% |
| FY2021 | 2021-12-31 | 170.25M | — |
EBITDA vs competitors
How ENOV compares with its peers on the latest reported figures
- ENOV's LTM Apr 2026 EBITDA of -$748.33M is the lowest of the 16 companies compared; the peer median is $170.4M.
- Its year-over-year change of -58.6% is the 15th highest of 16, against a peer median of +6.1%.
- EBITDA amounts to 32.8% of revenue for ENOV, versus a peer median of 18.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $957.8M | +12.1% | -0.2% | 26.7% | |
| LTM Jul 2026 | $927.7M | +9.7% | +13.3% | 19.6% | |
| LTM Jul 2026 | $621.8M | +1.0% | +2.3% | 16.0% | |
| LTM Jun 2026 | $578.7M | +23.0% | +13.2% | 21.6% | |
| LTM Sep 2026 | $346.92M | +35.2% | -3.4% | 15.3% | |
| LTM Jul 2026 | $231.96M | +9.1% | +0.5% | 20.1% | |
| LTM Jun 2026 | $199.9M | -20.2% | +5.2% | 16.3% | |
| LTM Jul 2026 | $170.4M | +21.0% | -8.2% | 19.1% | |
| LTM Feb 2026 | $139.45M | +2.1% | +45.0% | 22.3% | |
| LTM Jun 2026 | $129.99M | +8.6% | +30.4% | 18.5% | |
| LTM Mar 2026 | $35.7M | -25.6% | -15.4% | 9.6% | |
| LTM Mar 2026 | $22.65M | +6.1% | +43.7% | 9.2% | |
| LTM Mar 2026 | $18.38M | -23.4% | -13.7% | 18.7% | |
| LTM Apr 2026 | -$8.47M | -39.5% | — | 4.7% | |
| LTM Jul 2026 | -$22.18M | -102.9% | -4.9% | 0.6% | |
| LTM Apr 2026 | -$748.33M | -58.6% | — | 32.8% | |
| Peer median (excluding ENOV) | $170.4M | +6.1% | +1.4% | 18.5% | |
Competitors are the stored peer set for ENOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.43B | 1.56B | 1.71B | 2.11B | 2.25B |
| Cost of Revenue | 648.51M | 693.72M | 716.42M | 926.87M | 902.79M |
| Gross Profit | 777.68M | 869.38M | 990.78M | 1.18B | 1.35B |
| Gross Margin | 54.5% | 55.6% | 58.0% | 56.0% | 59.8% |
| Research & Development | 49.09M | 60.83M | 75.33M | 91.3M | 120.33M |
| Selling, General & Admin | 665.78M | 772.91M | 830.31M | 939.36M | 1.07B |
| Operating Expenses | 840.47M | 940.56M | 1.06B | 1.96B | 1.36B |
| Depreciation & Amortization | 262.92M | 219.71M | 217.11M | 284.8M | 294.38M |
| EBITDA | 170.25M | 241.69M | 169.73M | (481.03M) | (830.22M) |
| EBITDA Margin | 11.9% | 15.5% | 9.9% | -22.8% | -36.9% |
| Operating Income | (62.8M) | (71.18M) | (65.71M) | (775.72M) | (18.87M) |
| Operating Margin | -4.4% | -4.6% | -3.8% | -36.8% | -0.8% |
| Interest Income | 0 | 200K | 0 | 0 | 0 |
| Interest Expense | 29.11M | 24.95M | 19.75M | 57.1M | 34.82M |
| Other Income / Expenses | (58.98M) | 69.11M | (1.42M) | (47.21M) | (1.14B) |
| Income Before Tax | (121.78M) | (2.07M) | (67.13M) | (822.92M) | (1.16B) |
| Pre-Tax Margin | -8.5% | -0.1% | -3.9% | -39.0% | -51.6% |
| Income Tax Expense | (19.53M) | 36.12M | (13.29M) | 4.49M | 22.29M |
| Net Income | 71.66M | (13.29M) | (33.26M) | (825.49M) | (1.18B) |
| Net Margin | 5.0% | -0.9% | -1.9% | -39.2% | -52.7% |
| EPS (Basic) | (2.02) | (0.28) | (0.61) | (14.93) | (20.86) |
| EPS (Diluted) | (2.02) | (0.28) | (0.61) | (14.93) | (20.86) |
| Weighted Avg Shares | 51.14M | 54.07M | 54.53M | 55.28M | 56.79M |
| Weighted Avg Shares (Diluted) | 51.14M | 54.07M | 54.49M | 55.28M | 56.79M |
Enovis Corporation
NYSE:ENOV
Intrinsic Alpha fair value
Locked
Current Price
$27.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.